Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Aspire Biopharma (Nasdaq: ASBP) regained compliance with Nasdaq Listing Rule 5550(a)(2) after achieving a closing bid of at least $1.00 per share for 10 consecutive business days, and Nasdaq confirmed the matter is closed on February 10, 2026.
The company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement and says it has made progress on strategic plans for 2026 with additional details to follow.
Positive
- Regained Nasdaq minimum bid compliance after 10 consecutive business days
- Nasdaq confirmed the listing deficiency matter is closed
- Company signals progress on 2026 strategic plans
Negative
- Still subject to extension to meet $2.5 million stockholders' equity requirement
Key Figures
Market Reality Check
Peers on Argus
ASBP was down 1.37% while close biotech peers showed mixed moves (e.g., XCUR up 8.66%, CRIS down 5.02%, ICU up 1.25%). Scanner data flags no coordinated sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Product marketing update | Positive | -14.8% | Subsidiary showcasing BUZZ BOMB™ at a major sports nutrition summit. |
| Feb 03 | Distribution partnership | Positive | -4.1% | Buzz Bomb signs Blue Shark Beverages deal to expand SoCal distribution. |
| Jan 29 | Clinical development deal | Positive | -8.2% | Agreement with Microsize for 162 mg sublingual aspirin formulation and trial prep. |
| Jan 27 | Patent application | Positive | -8.5% | Provisional patent for sublingual clopidogrel powder via 505(b)(2) pathway. |
| Jan 22 | Consumer scale-up | Positive | -5.2% | Delivery of two million BUZZ BOMB™ units and 100,000 20-packs inventory. |
Recent ostensibly positive business and pipeline updates have been followed by negative 24-hour price reactions.
Over the last few weeks, ASBP announced consumer expansion for BUZZ BOMB™, new Southern California distribution, a Microsize agreement for a 162 mg sublingual aspirin program, and a provisional patent for sublingual clopidogrel. It also scaled its consumer division with delivery of two million BUZZ BOMB™ units. Despite these developments, each event saw a negative next-day move between about -4% and -15%, suggesting a pattern of selling into news before this Nasdaq compliance update.
Market Pulse Summary
This announcement confirms Nasdaq compliance with the $1.00 minimum bid requirement after 10 consecutive qualifying closes, removing one element of delisting risk. ASBP still needs to meet the $2.5 million stockholders’ equity requirement and trades at $1.44, far below its $394.40 52-week high. Recent news flow has centered on product launches, partnerships, and pipeline work, but those updates have coincided with negative short-term price reactions, highlighting ongoing execution and capital-structure risks to watch.
Key Terms
minimum bid price regulatory
stockholders' equity financial
AI-generated analysis. Not financial advice.
Company achieves minimum
ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of
The Company has made meaningful progress on its strategic plans for 2026 and expects to share additional details in the coming weeks. The Company believes that regaining compliance with this listing requirement positions it well for 2026.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Aspire Biopharma (ASBP) announce on February 10, 2026 about Nasdaq compliance?
Does Aspire Biopharma (ASBP) still face any Nasdaq listing conditions after February 10, 2026?
How might regaining Nasdaq compliance affect ASBP shareholders in 2026?
When will Aspire Biopharma (ASBP) provide more details on its 2026 strategic plans?
